TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Endurance Performance: VO2max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion of forearm supination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous use of the involved extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants who Complete FIT Test by Month 6
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of the program and research study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability by patients and clinicians
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Actual usage over 90 days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptable completion of iLookOut Micro-learning program
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Feasibility of iLookOut micro-learning program measured by learner satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intensity of skin sclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Peptides extracted from ocular tear samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolites extracted from ocular tear samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of persistent subjective complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Absence of peri-implant infection
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate and severity of solicited adverse events that are Grade 2 or above
Endpoint domain: Adverse events/effects
Primary endpoint: Rate and severity of treatment-emerging unsolicited adverse events that are Grade 2 or above
Endpoint domain: Adverse events/effects
Primary endpoint: Rate and severity of participants with serious adverse events (SAEs) related to investigational product
Endpoint domain: Adverse events/effects
Primary endpoint: GOOSS 3 rate without MAE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treatment-Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Clinically Significant Physical Examination Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Changes From Baseline for Electrocardiograms (ECGs): RR Interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: monthly number of headache days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients returning to sports activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: variation in the Knee Society Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving Itch NRS4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving IGA-CPG-S-TS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The change of systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: insulin secretion in response to oral glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: self-reported cybersickness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-16673
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Median Progression Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Median Overall Survival Rates
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Reporting Dose-limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Treatment-emergent Adverse Events and Death
Endpoint domain: Adverse events/effects
Primary endpoint: SEVR probability at two years
Endpoint domain: Mortality/survival
Primary endpoint: Change in MG-ADL total score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cortical Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood-Oxygen-Level-Dependent (BOLD) Signal Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With AEs Considered by the Investigator to be Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With SAEs Considered by the Investigator to be Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Slow wave activity (SWA) during non-rapid eye movement sleep (NREM) stage N2/N3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graph-based neural connectivity measure of local efficiency of information transfer (Elocal) during wakefulness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graph-based neural connectivity measure of global information transfer (Eglobal) during ECT-induced seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean kurtosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs) and Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Overall Response Rate (ORR) as Determined by the Investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Task Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants with One or More Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Normalization of area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot ulcer recurrence during the 12-months follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic data respiratory sinus arrhythmia in patients with chest pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Autonomic data respiratory sinus arrhythmia in patients with syncope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Autonomic data respiratory sinus arrhythmia in patients post heart transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistency of semaglutide treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diversity and abundance of bacterial species in stool samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ability to achieve personal goals
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in knowledge regarding cancer clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in attitudes regarding cancer clinical trials
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference of interoception behavioural scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in brain electrophysiology during interoception processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association between oxytocin system and interoception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Expired Carbon Monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Access Site Complications
Endpoint domain: Adverse events/effects
Primary endpoint: percent change of anti-PLA2R antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healthy-related biochemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain score at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative pain score on coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants who Achieve Complete Response rate at 30 months (CR30)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants with Progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Adaptive Behavior Composite (ABC) Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life (time to return to normal life)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bone microarchitecture differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone material strength index (BMSi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events of special interests (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events (AE) in mothers, fetuses, and infants exposed to TZIELD during pregnancy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of maternal pregnancy-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Developmental outcomes of the infant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinically relevant barotrauma
Endpoint domain: Adverse events/effects
Primary endpoint: Time to complete TLT conversations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported acceptability of TLT conversations
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in peak rate of oxygen volume consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Post Test Probability (PPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Post Test Probability (NPV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with immune-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically important hypoglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shoulder Pain and Disability Index (SPADI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diurnal variation of cortisol levels in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual field sensitivity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA) letter score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean retinal sensitivity change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants achieving a peak gastric eosinophil count of ≤6 eosinophils/high power field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Absolute change in the Eosinophilic Gastritis/Eosinophilic Duodenitis Symptom Questionnaire Total Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Long-term safety of EBT-101
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment Success in Generalized Pustular Psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success in Erythrodermic Psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment with no grade 3 GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Frustration rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of semaglutide
Endpoint domain: Adverse events/effects
Primary endpoint: Firing rate (Hz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in 28-day average seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adverse and disease-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of study protocol - retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of study protocol - telehealth
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of intervention - group attendance
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Percentage of Participants Achieving Pain Freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of Confusion Assessment Method - Postanesthetic Care Unit (CAM-PACU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Postoperative delirium after discharge from Postanesthetic Care Unit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical improvement on dupilumab therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective radiographic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative change in body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants who achieve body weight reduction >= 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of subjects with laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in ADHD-RS-IV-P Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABC-C FXS Pre-specified Subscale 1 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pTR rate (viable tumor in 50% or less of the surgically resected primary tumor bed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intracranial Pressure (ICP) measured by Transcranial Doppler (TCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: High Sensitivity C-Reactive Protein (hsCRP) ≥2 mg/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average daily area under curve (AUC) for serum sodium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Long-term serum sodium change (before/after treatment)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Assessment of pain (NRS) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total postoperative tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean change in ACQ-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average text message completion rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in VCF-related Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vertical Bone Height (Bone Gain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Bone Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: left ventricular systolic function recovery by ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: left ventricular systolic function recovery by STE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Humoral Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Eligible Patients Who Are Randomized
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Comfort sedation defined by target RASS score of -4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression score change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Cochlear Implant Quality of Life-35 Profile
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: International Prostate Symptom Score (IPSS) change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: California Learning Verbal Test III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Best objective response rate (ORR) - cohort A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best objective response rate (ORR) - cohort B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cornea and conjunctiva staining (Oxford scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Eye outcomes
Primary endpoint: Resting-state EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral indices in the tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Task-based EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Whole-body lean mass (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Millimetric landmark changes of hard and soft tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete metabolic response (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive Birth Perception Awareness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with Detectable Anti-Drug Antibodies (ADAs)
Endpoint domain: Adverse events/effects
Primary endpoint: Cigarette Smoking Abstinence Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mMASI scoring of melasma severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Occurrence of School Shooting
Endpoint domain: Mortality/survival
Primary endpoint: Illicit substance reuse rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of genetic counseling skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remineralization of early carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Maximum tolerated dose (MTD) of reirradiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gut health deficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number and nature of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Molecular Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in 24-hour urine protein creatinine ratio (UPCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cardiovascular reflex test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sudomotor function test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, relationship and severity of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in baseline laboratory values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fetal/Infant Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants Who Discontinue Study Treatment Due to AE
Endpoint domain: Adverse events/effects
Primary endpoint: Fallopian tube adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Oral and Pharyngolaryngeal Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gambling Follow up scale (GFS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Best corrected distant visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in opioid medication misuse
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline VABS-3 Communication Domain Standard Score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Griffiths III Language and Communication Developmental Quotient at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study Drug Adherence by drug accounting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes